

Tim Holland-Letz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7347635/publications.pdf>

Version: 2024-02-01

29
papers

4,097
citations

430874

18
h-index

454955

30
g-index

32
all docs

32
docs citations

32
times ranked

3416
citing authors

#	ARTICLE	IF	CITATIONS
1	The diagnostic value of PET/CT imaging with the ⁶⁸ Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 197-209.	6.4	866
2	Comparison of PET imaging with a ⁶⁸ Ga-labelled PSMA ligand and ¹⁸ F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 11-20.	6.4	817
3	PET imaging with a [⁶⁸ Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 486-495.	6.4	773
4	Diagnostic performance of ⁶⁸ Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1258-1268.	6.4	425
5	The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1697-1705.	5.0	332
6	Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2045-2054.	6.4	116
7	The Clinical Impact of Additional Late PET/CT Imaging with ⁶⁸ Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 750-755.	5.0	105
8	Intra-individual comparison of ⁶⁸ Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1400-1406.	6.4	101
9	Intraindividual Comparison of ¹⁸ F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1805-1810.	5.0	91
10	Diagnostic Accuracy of ¹⁸ F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence. <i>Journal of Nuclear Medicine</i> , 2021, 62, 208-213.	5.0	77
11	Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with ¹³¹ I-MIP-1095. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 950-959.	6.4	69
12	⁶⁸ Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients. <i>Journal of Nuclear Medicine</i> , 2019, 60, 234-240.	5.0	49
13	Performance of [⁶⁸ Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy—a multi-centre evaluation of 2533 patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2925-2934.	6.4	43
14	Intraindividual Comparison of ^{99m} Tc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand ^{99m} Tc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1373-1379.	5.0	31
15	Optimal experimental designs for dose-response studies with continuous endpoints. <i>Archives of Toxicology</i> , 2015, 89, 2059-2068.	4.2	29
16	⁶⁸ Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1949-1955.	5.0	27
17	Tracer uptake in mediastinal and paraaortal thoracic lymph nodes as a potential pitfall in image interpretation of PSMA ligand PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1179-1187.	6.4	26
18	⁶⁸ Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer—a modified protocol compared with the common protocol. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 624-631.	6.4	26

#	ARTICLE	IF	CITATIONS
19	Reply to Reske et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 971-972.	6.4	20
20	Comparison of PSMA-ligand PET/CT and multiparametric MRI for the detection of recurrent prostate cancer in the pelvis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2289-2297.	6.4	19
21	Predicting the Risk of Metastases by PSMA-PET/CT Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma. <i>Cancers</i> , 2021, 13, 1508.	3.7	8
22	On the Combination of <i>c</i> - and <i>D</i> -Optimal Designs: General Approaches and Applications in Dose-Response Studies. <i>Biometrics</i> , 2017, 73, 206-213.	1.4	7
23	Optimal experimental designs for estimating the drug combination index in toxicology. <i>Computational Statistics and Data Analysis</i> , 2018, 117, 182-193.	1.2	7
24	Efficient Algorithms for Optimal Designs with Correlated Observations in Pharmacokinetics and Dose-Finding Studies. <i>Biometrics</i> , 2012, 68, 138-145.	1.4	6
25	Parametric modeling and optimal experimental designs for estimating isobolograms for drug interactions in toxicology. <i>Journal of Biopharmaceutical Statistics</i> , 2018, 28, 763-777.	0.8	4
26	Modeling dose-response functions for combination treatments with log-logistic or Weibull functions. <i>Archives of Toxicology</i> , 2020, 94, 197-204.	4.2	4
27	An R-shiny application to calculate optimal designs for single substance and interaction trials in dose response experiments. <i>Toxicology Letters</i> , 2021, 337, 18-27.	0.8	2
28	The design heatmap: A simple visualization of optimality design problems. <i>Biometrical Journal</i> , 2020, 62, 2013-2031.	1.0	1
29	Drawing statistical conclusions from experiments with multiple quantitative measurements per subject. <i>Radiotherapy and Oncology</i> , 2020, 152, 30-33.	0.6	1